News
Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund
BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.i6864 (Published 03 January 2017) Cite this as: BMJ 2017;356:i6864
- Ingrid Torjesen
- London
The liver cancer treatment sorafenib should not be available routinely in the NHS in England, but it should continue to be available through the Cancer Drugs Fund, the National Institute for Health and Care Excellence (NICE) has recommended in draft guidance.
NICE originally published guidance in 2010 saying that sorafenib was not cost effective, even though it had considered the drug under its higher cost per quality adjusted life year (QALY) criterion for end of life treatments and …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.